A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse
Language English Country Austria Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acoustics MeSH
- Analysis of Variance MeSH
- Antiparkinson Agents therapeutic use MeSH
- Adult MeSH
- Dysarthria etiology MeSH
- Dystonia etiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Parkinsonian Disorders drug therapy etiology MeSH
- Substance-Related Disorders complications MeSH
- Propiophenones adverse effects MeSH
- Statistics as Topic MeSH
- Severity of Illness Index MeSH
- Mental Status Schedule MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antiparkinson Agents MeSH
- monomethylpropion MeSH Browser
- Propiophenones MeSH
A distinctive alteration of speech has been reported in patients suffering from ephedrone-induced parkinsonism. However, an objective assessment of dysarthria has not been performed in ephedrone users. We studied 28 young Caucasian men from Georgia with a previous history of ephedrone abuse and compared them to 25 age-matched healthy controls. Speech examination, brain MRI, and NNIPPS-Parkinson plus scale were performed in all patients. The accurate differential diagnosis of dysarthria subtypes was based on the quantitative acoustic analyses of 15 speech dimensions. We revealed a distinct variant of mixed dysarthria with a combination of hyperkinetic and hypokinetic components representing the altered motor programming of dystonia and bradykinesia in ephedrone-induced parkinsonism. According to acoustic analyses, all patients presented at least one affected speech dimension, whereas dysarthria was moderate in 43% and severe in 36% of patients. Further findings indicated relationships between motor subscores of dystonia and bradykinesia and speech components of loudness (r = -0.54, p < 0.01), articulation (r = 0.40, p < 0.05), and timing (r = -0.53, p < 0.01). In ephedrone-induced parkinsonism a prominent mixed hyperkinetic-hypokinetic dysarthria occurs that appears related to marked dystonia and bradykinesia and probably reflects manganese induced toxic and neurodegenerative damage to the globus pallidus internus and substantia nigra.
See more in PubMed
J Psychiatr Res. 1975 Nov;12(3):189-98 PubMed
Mov Disord. 2009 May 15;24(7):1001-8 PubMed
J Neural Transm (Vienna). 2010 May;117(5):605-12 PubMed
Neurosci Lett. 1993 Nov 12;162(1-2):192-6 PubMed
Neurology. 2000 Dec 12;55(11):1621-6 PubMed
Metab Brain Dis. 1995 Dec;10(4):259-67 PubMed
J Acoust Soc Am. 2001 May;109(5 Pt 1):2181-9 PubMed
Mov Disord. 2008 Nov 15;23(15):2224-31 PubMed
Brain Lang. 2002 Jul;82(1):65-74 PubMed
Mov Disord. 2007 Jul 15;22(9):1337-43 PubMed
Neuropsychologia. 1999 Dec;37(13):1453-60 PubMed
J Neurol Sci. 1973 Dec;20(4):415-55 PubMed
J Speech Hear Res. 1969 Jun;12(2):246-69 PubMed
Trends Neurosci. 1989 Oct;12(10):366-75 PubMed
Arch Gen Psychiatry. 1961 Jun;4:561-71 PubMed
J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed
N Engl J Med. 2008 Mar 6;358(10):1009-17 PubMed
J Neurosurg. 1997 Oct;87(4):491-8 PubMed
Parkinsons Dis. 2011 Feb 17;2011:865319 PubMed
Arch Neurol. 2005 Sep;62(9):1385-90 PubMed
J Speech Lang Hear Res. 2007 Aug;50(4):899-912 PubMed
J Neural Transm (Vienna). 2013 Feb;120(2):319-29 PubMed
PLoS One. 2011;6(8):e22293 PubMed
Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(7):12-20 PubMed
J Commun Disord. 2010 Jan-Feb;43(1):21-34 PubMed
PLoS One. 2013 Jun 10;8(6):e65881 PubMed
J Neuropathol Exp Neurol. 2007 Aug;66(8):675-82 PubMed
Neurotoxicology. 2006 May;27(3):340-6 PubMed
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy
Effect of pallidal deep-brain stimulation on articulation rate in dystonia
Phonatory dysfunction as a preclinical symptom of Huntington disease
